<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B80FA015-FF48-471E-839C-CB0CD2B7E9AD"><gtr:id>B80FA015-FF48-471E-839C-CB0CD2B7E9AD</gtr:id><gtr:name>Imanova</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8D55713A-87FD-4232-B50F-49BB01546C91"><gtr:id>8D55713A-87FD-4232-B50F-49BB01546C91</gtr:id><gtr:name>GE (General Electric Company)</gtr:name><gtr:address><gtr:line1>General Electric Company</gtr:line1><gtr:line2>3135 Easton Turnpike</gtr:line2><gtr:postCode>06828</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B80FA015-FF48-471E-839C-CB0CD2B7E9AD"><gtr:id>B80FA015-FF48-471E-839C-CB0CD2B7E9AD</gtr:id><gtr:name>Imanova</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8D55713A-87FD-4232-B50F-49BB01546C91"><gtr:id>8D55713A-87FD-4232-B50F-49BB01546C91</gtr:id><gtr:name>GE (General Electric Company)</gtr:name><gtr:address><gtr:line1>General Electric Company</gtr:line1><gtr:line2>3135 Easton Turnpike</gtr:line2><gtr:postCode>06828</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C67373B7-D390-4D49-BD31-1280BA65D1F5"><gtr:id>C67373B7-D390-4D49-BD31-1280BA65D1F5</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Nutt</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C9EF0FB5-941A-47D1-AB13-A6115D438A18"><gtr:id>C9EF0FB5-941A-47D1-AB13-A6115D438A18</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:otherNames>M</gtr:otherNames><gtr:surname>Matthews</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7B26620B-FEB9-4EF6-884F-8670FC59E3D6"><gtr:id>7B26620B-FEB9-4EF6-884F-8670FC59E3D6</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Brooks</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0900897"><gtr:id>1D621896-E843-478D-9CE8-C030E61E0D13</gtr:id><gtr:title>MRC Collaborative Training Programme in Radiochemistry for NeuroPET</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0900897</gtr:grantReference><gtr:abstractText>Positron emission tomography or PET allows the amount and position of specific molecules to be mapped non-invasively using sensitive detectors of very low level, relatively safe radioactively tagged tracers. In the ideal case, the method could provide critical diagnostic information for the diagnosis of major diseases such as Alzheimer s disease long before symptoms may appear. The methods also can be used to help better ensure that the right dose of experimental drugs are used in clinical trials, increasing the likelihood of successful completion of the trials. However, while the UK has equipment that could allow a high level of this activity at several major academic hospitals, there are not enough chemists specially trained to develop and produce the radiotracers. This proposal would create a novel 4 year training programme- really a world first - to equip two chemists with the skills and experience to become UK leaders in this area. In addition, the grant will bring together centres that previously have not worked together, allowing them to begin to pool resources for common good.</gtr:abstractText><gtr:technicalSummary>This proposal is to establish a pilot advanced neuroPET radiochemistry training programme linking major centres for molecular imaging in the UK in a collaborative network. The programme will be aimed at post-doctoral chemists. Two four-year training fellowships will be created by our programme. The initial two years of each will be focused on developing foundation skills in a structured, ?hands-on? pedagogical framework. In the latter six months of this two-year foundation training period, trainees will take on a mentored evaluation of potential approaches for new neuroPET radiotracer refinement or development. In the final two years of the programme, trainees then will work in one of the collaborative sites as the lead in a programme to develop one such radiotracer concept. The new radiotracer development will be pursued in a way that will allow the rapid translation of the work to benefit multiple partners in the collaborative network (and others). The outcomes of this programme will include new collaborative partnerships between UK molecular imaging centres, newly trained radiochemists able to lead independent programmes and a contribution to the development or refinement of novel PET molecular imaging radiotracers.</gtr:technicalSummary><gtr:fund><gtr:end>2014-02-08</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-08-09</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>599998</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Psychiatry</gtr:department><gtr:description>Psychiatry</gtr:description><gtr:id>98E56962-B5C7-479A-A474-71462325A1B4</gtr:id><gtr:impact>Multiple papers- support for new grants to Profs. Cowen and James</gtr:impact><gtr:outcomeId>HFdEdExdGfQ-1</gtr:outcomeId><gtr:partnerContribution>Staff</gtr:partnerContribution><gtr:piContribution>Helping to define problem, experimental design, analysis, implrementation and interpretation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Radiochemistry</gtr:department><gtr:description>Training collaboration</gtr:description><gtr:id>91DB720F-8B1A-46E9-BDCF-7444AF398240</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>GHQgAYQHE2x-3</gtr:outcomeId><gtr:partnerContribution>Advice Joint planning for new radiotracer implementationProvided a training and collaborative environment</gtr:partnerContribution><gtr:piContribution>The research team joined with those from GE Amersham, The Wolfson laboratory at Manchester and Newcastle University to share information on PET radioligand approaches. Direct interactions now have been scheduled to continue.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GE Healthcare</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuclear Medicine</gtr:department><gtr:description>Training collaboration</gtr:description><gtr:id>FF39C966-53B1-4185-BBC4-87AD70C130AC</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>GHQgAYQHE2x-1</gtr:outcomeId><gtr:partnerContribution>Advice Joint planning for new radiotracer implementationProvided a training and collaborative environment</gtr:partnerContribution><gtr:piContribution>The research team joined with those from GE Amersham, The Wolfson laboratory at Manchester and Newcastle University to share information on PET radioligand approaches. Direct interactions now have been scheduled to continue.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imanova</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Training collaboration</gtr:description><gtr:id>24EEF876-FBAE-4F4E-AA34-F6522AE0BD3F</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>GHQgAYQHE2x-4</gtr:outcomeId><gtr:partnerContribution>Advice Joint planning for new radiotracer implementationProvided a training and collaborative environment</gtr:partnerContribution><gtr:piContribution>The research team joined with those from GE Amersham, The Wolfson laboratory at Manchester and Newcastle University to share information on PET radioligand approaches. Direct interactions now have been scheduled to continue.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>College of Life and Environmental Sciences</gtr:department><gtr:description>Birmingham</gtr:description><gtr:id>C01EA93A-E9D3-42E7-B77C-D1AE46374B48</gtr:id><gtr:impact>Univ Birmingham successfully submitted bid for their own imaging centre, which is thriving</gtr:impact><gtr:outcomeId>ota25ibpwbN-1</gtr:outcomeId><gtr:partnerContribution>Staff and collaborative approach to problem</gtr:partnerContribution><gtr:piContribution>Provided scanning facility, expertise in design, execution, analysis and interpretation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Wolfson Molecular Imaging Centre (WMIC)</gtr:department><gtr:description>Training collaboration</gtr:description><gtr:id>8917E9DA-1EE5-4922-AE7F-ECFF0C9D42D6</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>GHQgAYQHE2x-2</gtr:outcomeId><gtr:partnerContribution>Advice Joint planning for new radiotracer implementationProvided a training and collaborative environment</gtr:partnerContribution><gtr:piContribution>The research team joined with those from GE Amersham, The Wolfson laboratory at Manchester and Newcastle University to share information on PET radioligand approaches. Direct interactions now have been scheduled to continue.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>GSK Clinical Imaging Centre  (CIC)</gtr:department><gtr:description>GlaxoSmithKline Global Imaging Unit</gtr:description><gtr:id>7B170314-A88B-4502-9B39-F44C4E1C343C</gtr:id><gtr:impact>16 clinical fellows have been enrolled or have completed
Academic papers and 1 patent have resulted</gtr:impact><gtr:outcomeId>EJ7VpfWX25c-1</gtr:outcomeId><gtr:partnerContribution>Financial support and co-mentorship for students</gtr:partnerContribution><gtr:piContribution>Wellcome Trust-GSK Clinical Fellowships in Translational Medicine</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Cold Spring Harbour Interdisciplinary Art and Science meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8886BCA2-BDA5-4C04-B379-EFD84CB48DBD</gtr:id><gtr:impact>Educated artists,writers in methods of science

Follow up invitation to 2013 ICLA</gtr:impact><gtr:outcomeId>GSzYpX83szH</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Exploring Canada-UK-US Synergies for Medical Imaging, London</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FBF4BF4E-566A-4ACD-8D64-D35B11D17109</gtr:id><gtr:impact>Exploring Canada-UK-US Synergies for Medical Imaging, Canadian High Commission, London, 30 June 2011 -Advanced imaging for experimental medicine in oncology: opportunities and challenges 


Improved use of molecular imaging by industry</gtr:impact><gtr:outcomeId>ZsAacB5YQBj</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Showcasing British Neuroscience, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FE21E78F-FBF9-4623-BCF4-04F5A2A3EBB7</gtr:id><gtr:impact>Showcasing British Neuroscience, Wellcome Trust, London, February 2013 - A national effort for translational neuroscience and imaging

Commercial engagement with UK academic base</gtr:impact><gtr:outcomeId>CXRT1GtGdyc</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UniQ Summer School Lecture and Workshop, Oxford</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D5BEF099-7546-471D-AAEC-CA5ABAAAA5AA</gtr:id><gtr:impact>UniQ Summer School Lecture and Workshop, University of Oxford - 21 July 2010 - New drugs for the developing world


Expanding access to UK elite universities for school children</gtr:impact><gtr:outcomeId>fHJAfaEBxWY</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC - Japan Science and Technology Collaborative Workshop</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6D8C0FC1-3BD0-4490-9039-1F2BCD435898</gtr:id><gtr:impact>MRC - Japan Science and Technology Collaborative Workshop, Tokyo, 14 June 2012 - UK Imaging Science: an overview


Commercial engagement with UK academic base</gtr:impact><gtr:outcomeId>mZirjCDdRqg</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2750000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>WT-GSK Clinical Training Fellowships</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>FC131685-78DE-4836-BA52-20D1634AB020</gtr:id><gtr:outcomeId>KuEjzZfhKAP</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Public consultation roll out of participant involvement in research- MRC/WT sponsorted</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>915E4652-5AAE-4742-AC2A-98AA57EAE1BE</gtr:id><gtr:impact>Changes in perception of clinical trials</gtr:impact><gtr:outcomeId>dQCnSGkCfS7</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Post-Weatherall Panel to review UK Primate Research</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B8FE0A2B-3FD1-4E6D-B180-CA13389C72D2</gtr:id><gtr:impact>Refinement of review procedures</gtr:impact><gtr:outcomeId>EHMP9Kcjetd</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Engagement with MHRA for establishing an expert or &amp;quot;superuser&amp;quot; group to help the UK community best respond to MHRA guidelines for PET</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DCF7C3AE-7BED-4B7F-85A9-CD368389E766</gtr:id><gtr:outcomeId>PYd5Wii4r3H</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Over last 5 years, research and group have contributed to development of more than 18 different molecules in early development (see letter from Dr. Phil Murphy in 2013 REF submission). Here these contributions all have been &amp;quot;lumped&amp;quot; into a single entry</gtr:description><gtr:id>399CE653-AEA2-454F-8931-E68181F2CCDA</gtr:id><gtr:impact>reducing costs for commercial development, increased competitiveness of UK environment</gtr:impact><gtr:outcomeId>tXGDdtoJD8n</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>GlaxoSmithKline Early Development</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>IL2 can be a used as a molecular probe for T-cells in humans. The work refined and evaluated a method for preparation that had been described by European collaborators. Unfortunately, we proved it to degrade the molecule and hence are developing new approaches.</gtr:description><gtr:id>2CEC9A19-5C99-4018-83A5-7CBF5AC634BA</gtr:id><gtr:impact>The work has informed R and D in GSK, which had been intending to apply the F-IL2 tracer</gtr:impact><gtr:outcomeId>KcMgWmrYqY3</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Evaluation of IL2 as a fluorinated PET tracer</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A number of radiotracers were newly implemented in the UK Imanova centre including rolipram, PBR28, PBR111 and additional work was done to make PE2I avaliable.</gtr:description><gtr:id>1A7D9C08-6D00-4463-82F0-3409F6EB6C0E</gtr:id><gtr:impact>GSK and Imperial college based resarchers are starting or preparing to start clinical studies.</gtr:impact><gtr:outcomeId>nbJWkEe4eEy</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Implementation of radiotracers for research use</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Imanova, Ltd.</gtr:companyName><gtr:description>Imanova is a molecular and functional imaging service company. This funding programme further demonstrated the value of public-private partnerships in this area to GSK, who led in formation of the new company. The programme continues to support Imanova and is not providing the latter with a model for training.</gtr:description><gtr:id>D7AC5250-51D9-45A3-9086-56A9C1035D9C</gtr:id><gtr:impact>Has established proof of principle for training in radiochemistry in the context of this kind of company</gtr:impact><gtr:outcomeId>JVeHPQVJ2cm</gtr:outcomeId><gtr:url>http://www.imanova.co.uk/</gtr:url><gtr:yearCompanyFormed>2011</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>F648C753-925F-4744-8E52-CC38DDDF819F</gtr:id><gtr:title>Determination of [(11)C]PBR28 binding potential in vivo: a first human TSPO blocking study.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfaffda7f0c70f3f89bd89295b524d5d"><gtr:id>cfaffda7f0c70f3f89bd89295b524d5d</gtr:id><gtr:otherNames>Owen DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>546135e09826d5.78963790</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0E60646-7B50-4F3C-B181-8B1D5099A0E0</gtr:id><gtr:title>Endogenous opioid release in the human brain reward system induced by acute amphetamine administration.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac374eaf02bb39818ac1a7a6da55fb05"><gtr:id>ac374eaf02bb39818ac1a7a6da55fb05</gtr:id><gtr:otherNames>Colasanti A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>Rz4nrQGCpoQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F3D6949-C8FD-491F-8BC1-F560AF5EE165</gtr:id><gtr:title>Orbitofrontal connectivity with resting-state networks is associated with midbrain dopamine D3 receptor availability.</gtr:title><gtr:parentPublicationTitle>Cerebral cortex (New York, N.Y. : 1991)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/732f61256c3633b35890ef412e768804"><gtr:id>732f61256c3633b35890ef412e768804</gtr:id><gtr:otherNames>Cole DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1047-3211</gtr:issn><gtr:outcomeId>pm_16326_26_22186675</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CEEEE843-286B-4E4A-9D23-3B437E6A07E8</gtr:id><gtr:title>Hippocampal Neuroinflammation, Functional Connectivity, and Depressive Symptoms in Multiple Sclerosis.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac374eaf02bb39818ac1a7a6da55fb05"><gtr:id>ac374eaf02bb39818ac1a7a6da55fb05</gtr:id><gtr:otherNames>Colasanti A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>56dee75d1f47a4.87549895</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1D5FBFF-4C99-4BA9-B053-85A11506CBA3</gtr:id><gtr:title>An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfaffda7f0c70f3f89bd89295b524d5d"><gtr:id>cfaffda7f0c70f3f89bd89295b524d5d</gtr:id><gtr:otherNames>Owen DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>PmG592fLBcG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E960508D-D798-4500-B2FA-56C78ADAB93D</gtr:id><gtr:title>Increased PK11195 PET binding in the cortex of patients with MS correlates with disability.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/003ef0c2090080af16a9718d5168846f"><gtr:id>003ef0c2090080af16a9718d5168846f</gtr:id><gtr:otherNames>Politis M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_16326_26_22764258</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>353369F3-DBE7-4623-9B0A-87642AB1A0A8</gtr:id><gtr:title>Neuroinflammation in treated HIV-positive individuals: A TSPO PET study.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4ebad27b7fb84463087c76cee951f25"><gtr:id>d4ebad27b7fb84463087c76cee951f25</gtr:id><gtr:otherNames>Vera JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>5aa19612b82258.40393995</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6ECA03F9-F5A4-4141-9A3D-C8836B1129F4</gtr:id><gtr:title>Thalamic inflammation after brain trauma is associated with thalamo-cortical white matter damage.</gtr:title><gtr:parentPublicationTitle>Journal of neuroinflammation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/071e882d6d5617fac73b55ac1d8145b1"><gtr:id>071e882d6d5617fac73b55ac1d8145b1</gtr:id><gtr:otherNames>Scott G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1742-2094</gtr:issn><gtr:outcomeId>56dee75d3f2215.72710510</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63C2AEF6-2D05-4FCA-A2A3-75DBA66974B9</gtr:id><gtr:title>The emerging agenda of stratified medicine in neurology.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/059fb6c1cfee8b9cd6e18e106d34b4e8"><gtr:id>059fb6c1cfee8b9cd6e18e106d34b4e8</gtr:id><gtr:otherNames>Matthews PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1759-4758</gtr:issn><gtr:outcomeId>XiQfMY4pfU9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9876ABF0-0963-4D0B-A431-16B1ED5DAB11</gtr:id><gtr:title>In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with (18)F-PBR111 PET.</gtr:title><gtr:parentPublicationTitle>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac374eaf02bb39818ac1a7a6da55fb05"><gtr:id>ac374eaf02bb39818ac1a7a6da55fb05</gtr:id><gtr:otherNames>Colasanti A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0161-5505</gtr:issn><gtr:outcomeId>546135e0c8e895.77091990</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49607BBA-9AE3-4991-95D7-E11FBA21FEB8</gtr:id><gtr:title>mutations in rats and a human polymorphism impair the rate of steroid synthesis.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfaffda7f0c70f3f89bd89295b524d5d"><gtr:id>cfaffda7f0c70f3f89bd89295b524d5d</gtr:id><gtr:otherNames>Owen DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>5a578be1e44113.98425373</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F0EC3D9-D524-4520-A810-4EB28F0D0DDA</gtr:id><gtr:title>Design, Synthesis, and Evaluation of Fluorinated Radioligands for Myelin Imaging.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4b3eb4c222546941a3c69ec561c908b"><gtr:id>c4b3eb4c222546941a3c69ec561c908b</gtr:id><gtr:otherNames>Tiwari AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>5aa196123b1e10.93562636</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20DE829D-306C-4940-8834-E6FCDF5402F1</gtr:id><gtr:title>Two binding sites for [3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfaffda7f0c70f3f89bd89295b524d5d"><gtr:id>cfaffda7f0c70f3f89bd89295b524d5d</gtr:id><gtr:otherNames>Owen DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>pm_16326_26_20424634</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDE51C72-1674-4112-BA1E-D981A4F103E5</gtr:id><gtr:title>Structural and functional bases for individual differences in motor learning.</gtr:title><gtr:parentPublicationTitle>Human brain mapping</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7eaf2bfa617f4a1c94169af19920c084"><gtr:id>7eaf2bfa617f4a1c94169af19920c084</gtr:id><gtr:otherNames>Tomassini V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1065-9471</gtr:issn><gtr:outcomeId>pm_16326_26_20533562</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE3DB679-CFD1-4607-A530-D5752261E2D0</gtr:id><gtr:title>Amyloid pathology and axonal injury after brain trauma.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/071e882d6d5617fac73b55ac1d8145b1"><gtr:id>071e882d6d5617fac73b55ac1d8145b1</gtr:id><gtr:otherNames>Scott G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>56dee75cd73e38.46309523</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5F22BF6-3A0C-4BCB-96DC-A2F8B5981CEA</gtr:id><gtr:title>Mixed-affinity binding in humans with 18-kDa translocator protein ligands.</gtr:title><gtr:parentPublicationTitle>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfaffda7f0c70f3f89bd89295b524d5d"><gtr:id>cfaffda7f0c70f3f89bd89295b524d5d</gtr:id><gtr:otherNames>Owen DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0161-5505</gtr:issn><gtr:outcomeId>tVfvKPwxuXp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DBC5D6C4-DA77-4662-AA02-840E657BC0FC</gtr:id><gtr:title>Decreased hippocampal translocator protein (18 kDa) expression in alcohol dependence: a [C]PBR28 PET study.</gtr:title><gtr:parentPublicationTitle>Translational psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/980cfcfb377e376208b8102e1ccf1bb0"><gtr:id>980cfcfb377e376208b8102e1ccf1bb0</gtr:id><gtr:otherNames>Kalk NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2158-3188</gtr:issn><gtr:outcomeId>5a6ef311acb908.80277151</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2005611C-70A7-40C5-BA40-B3577667BFDE</gtr:id><gtr:title>Pro-inflammatory activation of primary microglia and macrophages increases 18 kDa translocator protein expression in rodents but not humans.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfaffda7f0c70f3f89bd89295b524d5d"><gtr:id>cfaffda7f0c70f3f89bd89295b524d5d</gtr:id><gtr:otherNames>Owen DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>5a578c3866b387.66554702</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>678B6CEF-FE54-44E0-9A4F-D991BCA9CF22</gtr:id><gtr:title>Quantification of the specific translocator protein signal of 18F-PBR111 in healthy humans: a genetic polymorphism effect on in vivo binding.</gtr:title><gtr:parentPublicationTitle>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d97be839ee44a7633b43d8afe42e86ff"><gtr:id>d97be839ee44a7633b43d8afe42e86ff</gtr:id><gtr:otherNames>Guo Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0161-5505</gtr:issn><gtr:outcomeId>L4nWr68TCbP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A51ADE26-7351-4ABB-8427-8301DF75124E</gtr:id><gtr:title>Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/071e882d6d5617fac73b55ac1d8145b1"><gtr:id>071e882d6d5617fac73b55ac1d8145b1</gtr:id><gtr:otherNames>Scott G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5a5cce83afe9b3.08671056</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8637A1C5-B149-4685-B936-A1DA338CE439</gtr:id><gtr:title>Technologies: preclinical imaging for drug development.</gtr:title><gtr:parentPublicationTitle>Drug discovery today. Technologies</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/059fb6c1cfee8b9cd6e18e106d34b4e8"><gtr:id>059fb6c1cfee8b9cd6e18e106d34b4e8</gtr:id><gtr:otherNames>Matthews PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1740-6749</gtr:issn><gtr:outcomeId>BLcE18ZYuRM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7B526A5-DB19-4007-8496-40992958A156</gtr:id><gtr:title>Imaging brain microglial activation using positron emission tomography and translocator protein-specific radioligands.</gtr:title><gtr:parentPublicationTitle>International review of neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfaffda7f0c70f3f89bd89295b524d5d"><gtr:id>cfaffda7f0c70f3f89bd89295b524d5d</gtr:id><gtr:otherNames>Owen DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0074-7742</gtr:issn><gtr:outcomeId>pm_16326_26_22050847</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69BED5F8-6A4D-478D-A63C-B0FA601AE991</gtr:id><gtr:title>Brain activity changes associated with treadmill training after stroke.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c83282a7785f5c40cdb28461156eda7"><gtr:id>1c83282a7785f5c40cdb28461156eda7</gtr:id><gtr:otherNames>Enzinger C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>pm_16326_16_19461018</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1BFBEAEF-3631-492B-9890-57E74FA442E6</gtr:id><gtr:title>Positron emission tomography molecular imaging for drug development.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/059fb6c1cfee8b9cd6e18e106d34b4e8"><gtr:id>059fb6c1cfee8b9cd6e18e106d34b4e8</gtr:id><gtr:otherNames>Matthews PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>YGRocgnnYwG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>947E1E9D-843E-404C-8B5A-83AC98C64681</gtr:id><gtr:title>C-PBR28 andF-PBR111 Detect White Matter Inflammatory Heterogeneity in Multiple Sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0330c41be75a2674c561cb9317be1065"><gtr:id>0330c41be75a2674c561cb9317be1065</gtr:id><gtr:otherNames>Datta G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0161-5505</gtr:issn><gtr:outcomeId>5a6f0699e3f400.59016654</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>669F8FD0-9B1F-4E9E-B3A3-947CFAD0E4DA</gtr:id><gtr:title>Role of 18F-fluorodeoxyglucose Positron Emission Tomography in the Monitoring of Inflammatory Activity in Crohn's Disease.</gtr:title><gtr:parentPublicationTitle>Inflammatory bowel diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea1810bfbf20aa8b1d3749d38306c128"><gtr:id>ea1810bfbf20aa8b1d3749d38306c128</gtr:id><gtr:otherNames>Russo EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1078-0998</gtr:issn><gtr:outcomeId>5aa195a2b35611.12713548</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79274138-343B-4C9D-AB1C-91F9EE34E195</gtr:id><gtr:title>Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a769b727d029159d1ebe005981e71e85"><gtr:id>a769b727d029159d1ebe005981e71e85</gtr:id><gtr:otherNames>Rabiner EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>tieQrLjMyNB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3B4EBFFE-C41A-47EF-BC29-64FB75D81E31</gtr:id><gtr:title>Positron-emission tomography molecular imaging of glia and myelin in drug discovery for multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Expert opinion on drug discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/059fb6c1cfee8b9cd6e18e106d34b4e8"><gtr:id>059fb6c1cfee8b9cd6e18e106d34b4e8</gtr:id><gtr:otherNames>Matthews PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1746-0441</gtr:issn><gtr:outcomeId>56dee75dc45759.56765504</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15FEACBE-C88C-45E1-A55A-1D9AE7432B22</gtr:id><gtr:title>Non-invasive imaging in experimental medicine for drug development.</gtr:title><gtr:parentPublicationTitle>Current opinion in pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/059fb6c1cfee8b9cd6e18e106d34b4e8"><gtr:id>059fb6c1cfee8b9cd6e18e106d34b4e8</gtr:id><gtr:otherNames>Matthews PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1471-4892</gtr:issn><gtr:outcomeId>AWmhmx3nZCk</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0900897</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>